Hematopoietic stem cell transplantation for CTLA4 deficiency

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 2, 2016, Pages 615-619.e1

  Slatter, Mary A ^a,b   Engelhardt, Karin R ^a   Burroughs, Lauri M ^c,d   Arkwright, Peter D ^e   Nademi, Zohreh ^a,b   Skoda Smith, Suzanne ^c   Hagin, David ^c   Kennedy, Alan ^f   Barge, Dawn ^g   Flood, Terence ^a   Abinun, Mario ^a,b   Wynn, Robert F ^e   Gennery, Andrew R ^a,b   Cant, Andrew J ^a,b   Sansom, David ^f   Hambleton, Sophie ^a,b   Torgerson, Troy R ^c  

^a Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d USA   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g Regional Immunology Laboratory   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MELPHALAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN; CTLA4 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADOLESCENT; ALOPECIA; ARTHRITIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; BRONCHIECTASIS; CANCER CHEMOTHERAPY; CANCER RISK; CHILD; CHOLECYSTECTOMY; CLINICAL ARTICLE; COLITIS; CYTOPENIA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 DEFICIENCY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG MEGADOSE; ECZEMA; ENGRAFTMENT; ENTEROPATHY; FAMILY HISTORY; FEMALE; GRAFT VERSUS HOST REACTION; HAPLOINSUFFICIENCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LUNG ASPERGILLOSIS; LYMPHADENOPATHY; LYMPHOID HYPERPLASIA; MALE; MEDICAL HISTORY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCREAS INSUFFICIENCY; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SPLENECTOMY; STEROID THERAPY; THROMBOCYTOPENIA; TOTAL PARENTERAL NUTRITION; UNITED KINGDOM; UNITED STATES; UNSPECIFIED SIDE EFFECT; VITILIGO; ADULT; AMINO ACID SUBSTITUTION; CASE REPORT; DEFICIENCY; FRAMESHIFT MUTATION; GENETICS; IMMUNOLOGY; IMMUNOPATHOLOGY; MISSENSE MUTATION; MUTATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; CHILD; CTLA-4 ANTIGEN; FEMALE; FRAMESHIFT MUTATION; HAPLOINSUFFICIENCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE SYSTEM DISEASES; MALE; MUTATION; MUTATION, MISSENSE; TREATMENT OUTCOME;

EID: 84963815568     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.01.045     Document Type: Article

References (13)

1. 1 Kuehn, H.S., Ouyang, W., Lo, B., Deenick, E.K., Niemela, J.E., Avery, D.T., et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345 (2014), 1623–1627.
2. 2 Schubert, D., Bode, C., Kenefeck, R., Hou, T.Z., Wing, J.B., Kennedy, A., et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20 (2014), 1410–1416.
3. 3 Chambers, C.A., Sullivan, T.J., Allison, J.P., Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7 (1997), 885–895.
4. 4 Kumar, P., Henikoff, S., Ng, P.C., Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4 (2009), 1073–1081.
5. 5 Choi, Y., Sims, G.E., Murphy, S., Miller, J.R., Chan, A.P., Predicting the functional effect of amino acid substitutions and indels. PLoS One, 7, 2012, e46688.
6. 6 Schwarz, J.M., Cooper, D.N., Schuelke, M., Seelow, D., MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 11 (2014), 361–362.
7. 7 Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P., et al. Plymorphism phenotyping v2. Nat Methods 7 (2010), 248–249.
8. 8 Niroula, A., Urolagin, S., Vihinen, M., PON-P2: Prediction method for fast and reliable identification of harmful variants. PLoS ONE, 10, 2015, e0117380.
9. 9 Kircher, M., Witten, D.M., Jain, P., O'Roak, B.J., Cooper, G.M., Shendure, J., A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46 (2014), 310–315.
10. 10 Snowden, J.A., Pearce, R.M., Lee, J., Kirkland, K., Gilleece, M., Veys, P., et al., BSBMT Clinical Trials Committee. Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009. Br J Haematol 157 (2012), 742–746.
11. 11 Rao, K., Amrolia, P.J., Jones, A., Cale, C.M., Naik, P., King, D., et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 105 (2005), 879–885.
12. 12 Burroughs, L.M., Nemecek, E.R., Torgerson, T.R., Storer, B.E., Talano, J.A., Domm, J., et al. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. Biol Blood Marrow Transplant 20 (2014), 1996–2003.
13. 13 Lo, B., Zhang, K., Lu, W., Zheng, L., Zhang, Q., Kanellopoulou, C., et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science 349 (2015), 436–440.